Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma
Agenda
This program has been accredited for one hour of CME credit.
Optimizing BCMA-directed therapies: Balancing efficacy, safety, and patient-reported outcomes
The patient experience: Treatment with BCMA-directed therapies in relapsed multiple myeloma
Virtual exhibitor space
Following the close of the symposium, there will be an optional 'Virtual exhibitor space', providing an opportunity for further discussion and networking with the symposium speakers and GSK representatives.
Learning objectives
Following the symposium, learners will be able to:
- Explain the mechanism of action of different BCMA-directed therapies for the treatment of multiple myeloma.
- Recall key efficacy, safety, and patient-reported outcomes data from clinical trials and the real world for BCMA-directed therapies.
- State how treatment-specific adverse events can be identified early, monitored, and managed in clinical practice.
- Describe the rationale for selecting BCMA-directed therapies based on treatment-, disease-, and patient-related factors.
Our speakers
Meet our panel of experts
Rakesh Popat
University College London Hospitals
London, UK
Fredrik Schjesvold
Oslo Myeloma Center
Oslo, NO
Hang Quach
St Vincent's Hospital Melbourne
Melbourne, AU
Lynn Williams
Patient representative
London, UK
About SES
Delivering streamlined independent medical education to enhance clinical practice. SES hubs allow time-stretched healthcare professionals to easily access curated scientific, medical, and clinical information that expedites their learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies, our hubs support healthcare professionals worldwide with up-to-date, accessible, and impactful educational content.
About the Multiple Myeloma Hub
The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma, through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.
The Multiple Myeloma Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage with treatment teams and researchers around the world.